J & amp;J & #039;s Ethicon Spends $400M for Takeda ’s Fibrin Sealant Patch
Johnson & Johnson’s Ethicon is set to acquire Takeda Pharmaceutical’s Fibrin Sealant Patch for $400 million. The deal is set to close in the second half of 2019.
The TachoSil is a surgical patch designed to achieve safe fast and reliable bleeding control. Upon close, about 80 employees will transition to Ethicon. Takeda said net sales for TachoSil were about $155 million for the 2018 fiscal year.
Terms for the deal call for Ethicon to acquire the assets and licenses that support the manufacturing, licensing and commercialization of TachoSil, while Takeda maintains ownership of the ma...
Source: MDDI - May 9, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Digital Health Plays Larger Role in MDEA for 2019
For more than 20 the Medical Design Excellence Awards have celebrated medtech products that improve the quality of healthcare and accessibility. From prosthetic legs to breast pumps, over the years, MDEA has always been a spotlight of the greatest innovation in medtech.
This year was no different – with a wide variety of innovations coming from all segments of medtech. Just like any other year, jurors from all over the country shuffled into a conference room at the Anaheim Convention Center to see which products would be finalists for the MDEA. One trend seemed to stand out – the increas...
Source: MDDI - April 30, 2019 Category: Medical Devices Authors: Omar Ford Tags: Design News Source Type: news
Eisenhower Health first in Southern California to offer landmark treatment for COPD/emphysema
(Pulmonx) Eisenhower Health is the first hospital in Southern California to offer a new lung valve treatment for patients with severe COPD/emphysema. The Zephyr Endobronchial Valve treatment represents a major advancement because it is the first minimally invasive procedure to help emphysema sufferers breathe easier without major surgery. Done through a simple bronchoscopy, the valves improve patients' quality of life by allowing them to breathe easier, be less short of breath, and be more active and energetic. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 24, 2019 Category: International Medicine & Public Health Source Type: news
Lawsuits Put a Drag on J & amp;J 1Q19 Earnings
Legal costs surrounding Johnson and Johnson’s talc baby power and its blood thinner Xarleto bogged down the healthcare giant’s 1Q19 earnings. But while earnings from the New Brunswick, NJ-based company were down 14% from a year earlier, the firm managed to beat analyst expectations.
J&J posted income of $3.75 billion or $1.39 per share for 1Q19. In 1Q18, the company brought in $4.37 billion or $1.60 per share.
As a result, the healthcare company changed its full-year earnings forecast to a range of $8.53 to $8.63 a share, down from its previous estimate of between $8.50 and $8.65. Th...
Source: MDDI - April 16, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
Johnson & Johnson closes Auris Health buyout, sterilization biz sale
Johnson & Johnson (NYSE:JNJ) said yesterday that its Ethicon biz completed its $3.4 billion acquisition of robotic surgery dev Auris Health and the $2.8 billion divestiture of its Advanced Sterilization Products to Fortive (NTSE:FTV).
Redwood City, Calif.-based Auris Health, which was created by Intuitive Surgical (NSDQ:ISRG) founder and surgical robotics pioneer Dr. Fred Moll, developed and produces the robotic Monarch platform which has FDA clearance for diagnostic and therapeutic bronchoscopic procedures.
The Monarch system features a controller interface for navigating the integrated flexible robotic endoscope ...
Source: Mass Device - April 2, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Mergers & Acquisitions Robotics Sterilization / Calibration Wall Street Beat johnsonandjohnson Source Type: news
FDA clears Mauna Kea Technologies system for lung cancer detection
Mauna Kea Technologies’ Cellvizio system
Paris-based Mauna Kea Technologies (ENT:MKEA) said that it has received 510(k) clearance from FDA for the use of the Cellvizio AQ-Flex 19 Confocal Miniprobe through existing bronchoscopes, transbronchial needles, and other bronchoscopic accessories to detect lung cancer.
Cellvizio is a multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform designed to aid clinicians in the diagnosis and treatment of cancer and other diseases using real-time, in vivo microscopic visualization, according to the company. This marks the 16th 510(k) ...
Source: Mass Device - February 26, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: 510(k) Blog Diagnostics Food & Drug Administration (FDA) Imaging News Well Oncology Regulatory/Compliance Mauna Kea Technologies Source Type: news
Is J & amp;J Becoming a Surgical Robotics Powerhouse?
Johnson & Johnson is making some significant noise in the surgical robotics space today as it is announcing a deal that would have it acquire Auris Health for $3.4 billion. The deal also calls for additional contingent payments of up to $2.35 billion in the event of Auris reaching certain milestones. J&J would make the acquisition through its Ethicon subsidiary.
Redwood City, CA-based Auris Health develops robotic technologies that have been focused on lung cancer. The firm has the Monarch Platform, an FDA cleared system currently used in bronchoscopic diagnostic and therapeutic procedures.
In November of 2018, Aur...
Source: MDDI - February 13, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Digital Health Source Type: news
PETA: Cincinnati Children ’s agrees to halt use of live cats to train doctors
Cincinnati Children ’s Hospital executives ordered that live cats no longer be used to teach human bronchoscopy and intubation techniques to doctors from around the world, apparently following a complaint from People for the Ethical Treatment of Animals.
Physicians who teach a pediatric flexible bronchoscopy post-gr aduate course will no longer use animals, according to a Feb. 8 letter sent to PETA by Dr. Margaret Hostetter, chair of the Department of Pediatrics at Cincinnati’s largest hospital.
Hostetter… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 13, 2019 Category: American Health Authors: Barrett J. Brunsman Source Type: news
Johnson & Johnson delves into robotics, buys Auris Health for $3.4 billion
Johnson& Johnson, one of the largest maker of health products, is now in the robotics space.
The New Brunswick, New Jersey-based company announced Wednesday that it would buy surgery firm Auris Health for $3.4 billion in cash.
Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures.
This latest deal is expected to bolster Johnson& Johnson ’s entry… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 13, 2019 Category: Biotechnology Source Type: news
Johnson and Johnson Announces Agreement to Acquire Auris Health, Inc.
Auris Health's Robotic Platform Expands Johnson & Johnson's Digital Surgery Portfolio
NEW BRUNSWICK, N.J., Feb. 13, 2019 -- (Healthcare Sales & Marketing Network) -- Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today... Devices, Mergers & Acquisitions Johnson & Johnson, Auris Health, bronchoscopy, robotic (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2019 Category: Pharmaceuticals Source Type: news
J & J to enter the robotic surgery market with $3.4B Auris Health buy
Johnson & Johnson (NYSE:JNJ) is stepping into the field of robotic surgery after saying today that its Ethicon subsidiary inked a $3.4 billion deal to pick up surgical robotics pioneer Dr. Fred Moll’s newest robotic surgical play, Auris Health, and its FDA-cleared Monarch platform.
The New Brunswick, N.J.-based medtech giant said that the deal will include an additional $2.35 billion in milestone-based contingent payments, bringing the total value of the deal to approximately $5.75 billion.
Redwood City, Calif.-based Auris Health’s robotic Monarch platform has FDA clearance for diagnostic and therapeutic bron...
Source: Mass Device - February 13, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Mergers & Acquisitions Robotics Wall Street Beat aurishealth johnsonandjohnson Source Type: news
New assay selects patients with lung cancer for treatment with immune checkpoint inhibitors
(Elsevier) A report in The Journal of Molecular Diagnostics describes a novel and rapid approach for quantifying PD-L1 expression levels in tumors that requires only small amounts of tissue that can be collected using minimally invasive bronchoscopy techniques. This approach can also be used to discriminate malignant from benign tumors and identify mutational status, all of which can guide and refine therapeutic decisions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2019 Category: International Medicine & Public Health Source Type: news
Why Was This Nonsmoker Coughing for Months?
(MedPage Today) -- COPD inhaler didn ' t help, but bronchoscopy did (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - February 4, 2019 Category: Respiratory Medicine Source Type: news
Real-World Data on Medtronic & #039;s Lung Cancer Device Is Promising
Recently published results of a large, multicenter trial could go a long way toward boosting adoption of electromagnetic navigation bronchoscopy (ENB) procedures using Medtronic's superDimension navigation system to aid in lung cancer diagnosis, staging, and treatment. The 12-month results of the NAVIGATE study were published in the Journal of Thoracic Oncology.
"It's not enough anymore to just make a really amazing new technology, it has to be backed with clinical and economic evidence and one that allows really broad adoption around the globe to really impact as many patients as we can," Emily Elswick, vice p...
Source: MDDI - January 31, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Medtronic touts U.S. results of lung cancer detection trial
Partial results of a huge, real-world study of Medtronic’s (NYSE:MDT) superDimension LungGPS technology found that 65% of patients diagnosed with primary lung cancer (Stages I and II) were at early stages of the disease. Early detection of lung cancer is critical to improving patient outcomes long-term.
The results came from a 12-month follow-up of the 1,215-patient U.S. portion of the Navigate trial. Begun in 2015, the trial was designed to evaluate the performance of the LungGPS electromagnetic navigation bronchoscopy (ENB) technology that the superDimension device uses to navigate the lungs. Results from the Eu...
Source: Mass Device - January 30, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Clinical Trials Featured Oncology Covidien journalofthoraciconcology Medtronic Source Type: news
